Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application
- PMID: 38677545
- PMCID: PMC11976433
- DOI: 10.1016/j.jare.2024.04.016
Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application
Abstract
Background: N6-methyladenosine (m6A) RNA methylation modifications have been widely implicated in the metabolic reprogramming of various cell types within the tumor microenvironment (TME) and are essential for meeting the demands of cellular growth and maintaining tissue homeostasis, enabling cells to adapt to the specific conditions of the TME. An increasing number of research studies have focused on the role of m6A modifications in glucose, amino acid and lipid metabolism, revealing their capacity to induce aberrant changes in metabolite levels. These changes may in turn trigger oncogenic signaling pathways, leading to substantial alterations within the TME. Notably, certain metabolites, including lactate, succinate, fumarate, 2-hydroxyglutarate (2-HG), glutamate, glutamine, methionine, S-adenosylmethionine, fatty acids and cholesterol, exhibit pronounced deviations from normal levels. These deviations not only foster tumorigenesis, proliferation and angiogenesis but also give rise to an immunosuppressive TME, thereby facilitating immune evasion by the tumor.
Aim of review: The primary objective of this review is to comprehensively discuss the regulatory role of m6A modifications in the aforementioned metabolites and their potential impact on the development of an immunosuppressive TME through metabolic alterations.
Key scientific concepts of review: This review aims to elaborate on the intricate networks governed by the m6A-metabolite-TME axis and underscores its pivotal role in tumor progression. Furthermore, we delve into the potential implications of the m6A-metabolite-TME axis for the development of novel and targeted therapeutic strategies in cancer research.
Keywords: Cancer; Metabolites; Targeted therapy; Tumor immunosuppressive microenvironment; m(6)A.
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures





Similar articles
-
Role of m6A modifications in immune evasion and immunotherapy.Med Oncol. 2024 May 18;41(6):159. doi: 10.1007/s12032-024-02402-9. Med Oncol. 2024. PMID: 38761335 Review.
-
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.J Hematol Oncol. 2022 Jul 6;15(1):84. doi: 10.1186/s13045-022-01304-5. J Hematol Oncol. 2022. PMID: 35794625 Free PMC article. Review.
-
The evolving landscape of N6-methyladenosine modification in the tumor microenvironment.Mol Ther. 2021 May 5;29(5):1703-1715. doi: 10.1016/j.ymthe.2021.04.009. Epub 2021 Apr 9. Mol Ther. 2021. PMID: 33839323 Free PMC article. Review.
-
N6-methyladenosine RNA methylation, a new hallmark of metabolic reprogramming in the immune microenvironment.Front Immunol. 2024 Dec 20;15:1464042. doi: 10.3389/fimmu.2024.1464042. eCollection 2024. Front Immunol. 2024. PMID: 39759516 Free PMC article. Review.
-
N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.Front Immunol. 2021 Dec 9;12:773570. doi: 10.3389/fimmu.2021.773570. eCollection 2021. Front Immunol. 2021. PMID: 34956201 Free PMC article. Review.
Cited by
-
Glutamine-αKG axis affects dentin regeneration and regulates osteo/odontogenic differentiation of mesenchymal adult stem cells via IGF2 m6A modification.Stem Cell Res Ther. 2024 Dec 18;15(1):479. doi: 10.1186/s13287-024-04092-6. Stem Cell Res Ther. 2024. PMID: 39695862 Free PMC article.
-
Targeting glutamine metabolism as a potential target for cancer treatment.J Exp Clin Cancer Res. 2025 Jul 1;44(1):180. doi: 10.1186/s13046-025-03430-7. J Exp Clin Cancer Res. 2025. PMID: 40598593 Free PMC article. Review.
-
Distinct neurological phenotypes associated with biallelic loss of NOTCH3 function: evidence for recessive inheritance.Mol Biol Rep. 2024 Jun 1;51(1):714. doi: 10.1007/s11033-024-09560-z. Mol Biol Rep. 2024. PMID: 38824264
-
The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.Cell Biosci. 2025 Feb 22;15(1):27. doi: 10.1186/s13578-025-01368-z. Cell Biosci. 2025. PMID: 39987091 Free PMC article. Review.
-
Epigenetics-targeted drugs: current paradigms and future challenges.Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0. Signal Transduct Target Ther. 2024. PMID: 39592582 Free PMC article. Review.
References
-
- Deblois G., Tonekaboni S.A.M., Grillo G., Martinez C., Kao Y.I., Tai F., et al. Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast cancer. Cancer Discov. 2020;10(9):1312–1329. - PubMed
-
- Wang S., Sun C., Li J., Zhang E., Ma Z., Xu W., et al. Roles of RNA methylation by means of N(6)-methyladenosine (m(6)A) in human cancers. Cancer Lett. 2017;408:112–120. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials